Search

Your search keyword '"Péron, Julien"' showing total 303 results
Start Over Author "Péron, Julien"
Sorry, I don't understand your search. ×
303 results on '"Péron, Julien"'

5. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

Author

Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle L., Mirza, Mansoor R., Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, McNeish, Iain, Kelly, Caroline, Kagimura, Tatsuo, Welch, Stephen, Lewsley, Liz-Anne, Paoletti, Xavier, and Cook, Adrian

Published
2023
Full Text
View/download PDF

16. Difference Of Chemosensitivity Between Western And Japanese Women In First-Line Setting Of Advanced Serous Ovarian Cancer: Data From The MAOV Individual Patient Data Meta-Analysis

Author

Corbaux, Pauline, You, Benoit, Glasspool, Rosalind, Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle Laure, Mirza, Mansoor Raza, Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, Mcneish, Iain, Kelly, Caroline, Kagimura, Tatsuo, Welch, Stephen, Lewsley, Liz-Anne, Paoletti, Xavier, and Cook, Adrian

Published
2025
Full Text
View/download PDF

29. Supplementary Data from Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Author

Colomban, Olivier, primary, Tod, Michel, primary, Leary, Alexandra, primary, Ray-Coquard, Isabelle, primary, Lortholary, Alain, primary, Hardy-Bessard, Anne Claire, primary, Pfisterer, Jacobus, primary, Du Bois, Andreas, primary, Kurzeder, Christian, primary, Burges, Alexander, primary, Péron, Julien, primary, Freyer, Gilles, primary, and You, Benoit, primary

Published
2023
Full Text
View/download PDF

30. Data from Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Author

Colomban, Olivier, primary, Tod, Michel, primary, Leary, Alexandra, primary, Ray-Coquard, Isabelle, primary, Lortholary, Alain, primary, Hardy-Bessard, Anne Claire, primary, Pfisterer, Jacobus, primary, Du Bois, Andreas, primary, Kurzeder, Christian, primary, Burges, Alexander, primary, Péron, Julien, primary, Freyer, Gilles, primary, and You, Benoit, primary

Published
2023
Full Text
View/download PDF

34. Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study

Author

Maugeais, Madeleine, primary, Péron, Julien, additional, Dalle, Stéphane, additional, Boespflug, Amélie, additional, Duruissaux, Michaël, additional, Corbaux, Pauline, additional, Reverdy, Thibault, additional, Sahin, Gulsum, additional, Rabier, Aurélie, additional, Lopez, Jonathan, additional, Freymond, Nathalie, additional, and Maillet, Denis, additional

Published
2022
Full Text
View/download PDF

37. CD4 lymphopenia to identify end-of-life metastatic cancer patients

Author

Péron, Julien, Cropet, Claire, Tredan, Olivier, Bachelot, Thomas, Ray-Coquard, Isabelle, Clapisson, Gilles, Chabaud, Sylvie, Philip, Irene, Borg, Christophe, Cassier, Philippe, Labidi Galy, Inthidar, Sebban, Catherine, Perol, David, Biron, Pierre, Caux, Christophe, Menetrier-Caux, Christine, and Blay, Jean-Yves

Published
2013
Full Text
View/download PDF

40. Conception et production d'un guide patient pour accompagner la reprise du travail après un cancer du sein: une application de l'Intervention Mapping.

Author

Broc, Guillaume, Carretier, Julien, Rouat, Sabrina, Guittard, Laure, Péron, Julien, Fervers, Béatrice, Letrilliart, Laurent, Sarnin, Philippe, Fassier, Jean-Baptiste, and Lamort-Bouché, Marion

Subjects
PATIENT education, FOCUS groups, BREAST tumors, EMPIRICAL research, QUESTIONNAIRES, BEHAVIOR, CANCER patients, HEALTH planning, RESEARCH, MATHEMATICAL models, THEORY, PUBLIC health, HEALTH promotion, EMPLOYMENT reentry, INDUSTRIAL hygiene
Abstract

Copyright of Psycho-Oncologie is the property of PiscoMed Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

42. Scalloping of the Liver and Spleen on Preoperative CT-Scan of Pseudomyxoma Peritonei Patients: Impact on Prediction of Resectability, Grade, Morbidity and Survival

Author

Kepenekian, Vahan, primary, Kefleyesus, Amaniel, additional, Keskin, David, additional, Benzerdjeb, Nazim, additional, Bonnefoy, Isabelle, additional, Villeneuve, Laurent, additional, Alhadeedi, Omar, additional, Al-Otaibi, Abeer, additional, Galan, Alexandre, additional, Glehen, Olivier, additional, Péron, Julien, additional, and Rousset, Pascal, additional

Published
2022
Full Text
View/download PDF

44. Abstract 45: Screening somatic genomic alteration for rare adult cancers: the SPECTA-ARCAGEN project of the EORTC/EURACAN

Author

Morfouace, Marie, primary, Stevovic, Aleksandra, additional, Oliveira, Julio, additional, Penel, Nicolas, additional, Péron, Julien, additional, Casali, Paolo G., additional, SECKL, Michael J., additional, GIETEMA, Jourik A., additional, de HERDER, Wouter, additional, WYRWICZ, Lucjan, additional, de la FOUCHARDIERE, Christelle, additional, LICITRA, Lisa, additional, GIRARD, Nicolas, additional, PIPERNO-NEUMANN, Sophie, additional, KAPITEIJN, Ellen, additional, IDBAIH, Ahmed, additional, and Blay, Jean-Yves, additional

Published
2022
Full Text
View/download PDF

46. Survival Prognostic and Surrogate Values of the Early Modeled Ca-125 Kelim Score in First-Line Treatment of Ovarian Cancer: Results from The Gcig Individual Patient Data Meta-Analysis

Author

Corbaux, Pauline, primary, You, Benoit, additional, Glasspool, Rosalind M., additional, Yanaihara, Nozomu, additional, Tinker, Anna V., additional, Lindemann, Kristina, additional, Ray-Coquard, Isabelle-Laure, additional, Mirza, Mansoor Raza, additional, Subtil, Fabien, additional, Colomban, Olivier, additional, Péron, Julien, additional, Karamouza, Eleni, additional, McNeish, Iain, additional, Hinsley, Samantha, additional, Kagimura, Tatsuo, additional, Welch, Stephen, additional, Lewsley, Liz-Anne, additional, Paoletti, Xavier, additional, and Cook, Adrian, additional

Published
2022
Full Text
View/download PDF

47. COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study

Author

Péron, Julien, Dagonneau, Tristan, Conrad, Anne, Pineau, Fanny, Calattini, Sara, Freyer, Gilles, Perol, David, Sajous, Christophe, and Heiblig, Maël

Subjects
matched cohort study, COVID-19, cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, prognosis, mortality, Article, RC254-282
Abstract

Simple Summary Cancer patients have been described in previous studies as having a higher risk of contracting COVID-19 and a higher risk of developing a severe form of the disease. In this study, we compared a group of patients hospitalized for COVID-19 within the Lyon area with a matched group of patients free of cancer and also hospitalized for COVID-19. Cancer patients and control patients were matched in order to have a similar age, gender, and other preexisting conditions. In this study, the risk of death was higher among cancer patients, but the intensity of care was lower (lower access to intensive care unit, shorter length of stay). The risk of death among cancer patients appears to be mainly driven by the severity of the infection and therapeutic limitations decided at admission. Abstract It has been suggested that cancer patients are at higher risk of contracting COVID-19 and at higher risk of developing a severe form of the disease and fatality. This study’s objectives were to measure the excess risk of mortality and morbidity of patients with cancer among patients hospitalized for a SARS-CoV-2 infection, and to identify factors associated with the risk of death and morbidity among cancer patients. All first cancer patients hospitalized for COVID-19 in the two main hospitals of the Lyon area were included. These patients were matched based on age, gender, and comorbidities with non-cancer control patients. A total of 108 cancer patients and 193 control patients were included. The severity at admission and the symptoms were similar between the two groups. The risk of early death was higher among cancer patients, while the risk of intubation, number of days with oxygen, length of stay in ICU, and length of hospital stay were reduced. The main factors associated with early death among cancer patients was the severity of COVID-19 and the number of previous chemotherapy lines. The outcomes appear to be driven by the severity of the infection and therapeutic limitations decided at admission.

Published
2021

48. On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.

Author

De Backer, Mickaël, Legrand, Catherine, Péron, Julien, Lambert, Alexandre, and Buyse, Marc

Subjects
EXTREME value theory, PARETO distribution, KAPLAN-Meier estimator, CLINICAL trials, IMMUNOTHERAPY, TREATMENT effectiveness
Abstract

In randomized clinical trials, methods of pairwise comparisons such as the 'Net Benefit' or the 'win ratio' have recently gained much attention when interests lies in assessing the effect of a treatment as compared to a standard of care. Among other advantages, these methods are usually praised for delivering a treatment measure that can easily handle multiple outcomes of different nature, while keeping a meaningful interpretation for patients and clinicians. For time‐to‐event outcomes, a recent suggestion emerged in the literature for estimating these treatment measures by providing a natural handling of censored outcomes. However, this estimation procedure may lead to biased estimates when tails of survival functions cannot be reliably estimated using Kaplan–Meier estimators. The problem then extrapolates to the other outcomes incorporated in the pairwise comparison construction. In this work, we suggest to extend the procedure by the consideration of a hybrid survival function estimator that relies on an extreme value tail model through the Generalized Pareto distribution. We provide an estimator of treatment effect measures that notably improves on bias and remains easily apprehended for practical implementation. This is illustrated in an extensive simulation study as well as in an actual trial of a new cancer immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study.

Author

Maugeais, Madeleine, Péron, Julien, Dalle, Stéphane, Boespflug, Amélie, Duruissaux, Michaël, Corbaux, Pauline, Reverdy, Thibault, Sahin, Gulsum, Rabier, Aurélie, Lopez, Jonathan, Freymond, Nathalie, and Maillet, Denis

Subjects
IMMUNE checkpoint inhibitors, NON-small-cell lung carcinoma, SKIN cancer
Abstract

Background: ICIs have dramatically improved patient outcomes in different malignancies. However, the impact of liver metastases (LM) and number of metastatic sites (MS) remains unclear in patients treated with single-agent anti-PD(L)1. Methods: We aimed to assess the prognostic impact of LM and MS number on progression-free survival (PFS) and overall survival (OS) in a large single-arm retrospective multicentric cohort (IMMUCARE) of patients treated with anti-PD(L)-1 for different solid tumors. Results: A total of 759 patients were enrolled from January 2012 to October 2018. The primary tumor types were non-small cell lung cancer (71%), melanoma (19%), or urologic cancer (10%). At the time of ICI initiation, 167 patients (22%) had LM and 370 patients (49%) had more than MS. LM was associated with a shorter median PFS of 1.9 months (95% CI: 1.8–2.5) vs. 4.0 months (95% CI: 3.6–5.4) in patients without LM (p < 0.001). The median OS of patients with LM was of 5.2 months (95% CI: 4.0–7.7) compared with 12.8 months (95% CI: 11.2–15.1) (p < 0.001). Interestingly, LM were not associated with shorter PFS, or OS compared to other MS types (brain, bone, or lung) in patients with only one MS. Patients with multiple MS also had poor clinical outcomes compared to patients with only one MS. The presence of LM and MS number were independent prognostic factors on overall survival. Conclusion: The presence of LM or multiple MS were associated with poorer survival outcomes in patients treated with anti-PD(L)-1. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

Author

Kepenekian, Vahan, primary, Péron, Julien, additional, You, Benoit, additional, Bonnefoy, Isabelle, additional, Villeneuve, Laurent, additional, Alyami, Mohammad, additional, Bakrin, Naoual, additional, Rousset, Pascal, additional, Benzerdjeb, Nazim, additional, and Glehen, Olivier, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results